Cargando…

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients

Mycobacterium abscessus is difficult to eradicate. At the Montpellier CF Center, we prescribed liposomal amikacin for inhalation to 5 patients with M abscessus infection. The 3 patients who completed the treatment did not have any respiratory exacerbation, showed negative cultures for M abscessus in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caimmi, Davide, Martocq, Nicolas, Trioleyre, Delphine, Guinet, Catherine, Godreuil, Sylvain, Daniel, Thomas, Chiron, Raphael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846290/ https://www.ncbi.nlm.nih.gov/pubmed/29564361 http://dx.doi.org/10.1093/ofid/ofy034

Ejemplares similares

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience
por: Chiron, Raphael, et al.
Publicado: (2022)

Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
por: Henriette Zweijpfenning, Sanne Maria, et al.
Publicado: (2022)

Laryngitis after inhalation of liposomal amikacin
por: Morita, Atsuho, et al.
Publicado: (2022)

Mycobacterium chimaera Pulmonary Disease in Cystic Fibrosis Patients, France, 2010–2017
por: Larcher, Romaric, et al.
Publicado: (2019)

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis
por: Kidogawa, Moe, et al.
Publicado: (2022)

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Successful use of linezolid for refractory Mycobacterium abcessus infection: A case report
por: Inoue, Teppei, et al.
Publicado: (2017)

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Evaluating the efficacy of inhaled amikacin as an adjunct to intravenous combination therapy (ceftazidime and amikacin) in pediatric cystic fibrosis pulmonary exacerbation
por: Rakhshan, Amin, et al.
Publicado: (2023)

Several Nocardia abcessus bronchiolitis in a patient treated with inhaled corticosteroids: a case report
por: Cascarano, Estelle, et al.
Publicado: (2023)

Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey
por: Swenson, Colin, et al.
Publicado: (2020)

Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics
por: Caimmi, Silvia, et al.
Publicado: (2012)

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022)

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
por: Zhang, Jimin, et al.
Publicado: (2018)

Amikacin liposome and Mycobacterium avium complex: A systematic review
por: Zangiabadian, Moein, et al.
Publicado: (2022)

Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Rhinovirus‐associated pulmonary exacerbations show a lack of FEV (1) improvement in children with cystic fibrosis
por: Cousin, Mathias, et al.
Publicado: (2016)

805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
por: Brown-Elliott, Barbara A, et al.
Publicado: (2018)

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings
por: Morita, Atsuho, et al.
Publicado: (2022)

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats
por: Malinin, Vladimir, et al.
Publicado: (2016)

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
por: Khan, Omer, et al.
Publicado: (2020)

Blood co-expression modules identify potential modifier genes of diabetes and lung function in cystic fibrosis
por: Pineau, Fanny, et al.
Publicado: (2020)

Does amikacin treatment cause subclinical hearing loss in patients with cystic fibrosis?
por: Solmaz, Fevzi, et al.
Publicado: (2016)

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report
por: Hashimoto, Kazuki, et al.
Publicado: (2023)

Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
por: Kim, Bo-Guen, et al.
Publicado: (2020)

DNA Methylation at ATP11A cg11702988 Is a Biomarker of Lung Disease Severity in Cystic Fibrosis: A Longitudinal Study
por: Pineau, Fanny, et al.
Publicado: (2021)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis
por: Magalhães, Milena, et al.
Publicado: (2017)

Performance of amikacin inhale: impact of supplemental oxygen and device orientation
por: Kadrichu, N, et al.
Publicado: (2015)

Response to inhaled ceftazidime in patients with non‐cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to Pseudomonas aeruginosa
por: Riveiro, Vanessa, et al.
Publicado: (2022)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Sacroiliitis secondary to catheter-related bacteremia due to Mycobacterium abscessus (sensu stricto)
por: Laurens, Chrislène, et al.
Publicado: (2014)

Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus
por: Daniel-Wayman, Shelby, et al.
Publicado: (2019)

Inhaled ceftazidime and amikacin versus inhaled colistin in the treatment of gram negative ventilator associated pneumonia
por: Nassar, YS, et al.
Publicado: (2015)

Comparison of two-drug combinations, amikacin/tigecycline/imipenem and amikacin/tigecycline/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay
por: Portell-Buj, Elena, et al.
Publicado: (2021)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0s4tqojjll824pf1d3bf03f1rj